Epistem Signs $4M Biomarker Deal with Sanofi-Aventis; Preps PoC Platform for Companion Diagnostics | GenomeWeb

By Bernadette Toner

Epistem last week announced that it has signed a three-year collaboration with Sanofi-Aventis to use its proprietary biomarker discovery technology as part of the pharmaceutical firm's oncology programs.

The agreement, worth up to $4 million, will cover preclinical, ex vivo, and clinical studies and is aimed at providing Sanofi-Aventis with gene expression biomarkers that will identify patient response to drugs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.